[3-(4-tert-butylsulfonyl-2-chlorophenyl)azetidin-1-yl]-[(3S)-3-(2H-triazol-4-yl)pyrrolidin-1-yl]methanone
C20H26ClN5O3S — CID 175974827
Data last refreshed: (MolForge compound catalog, from PubChem)
About [3-(4-tert-butylsulfonyl-2-chlorophenyl)azetidin-1-yl]-[(3S)-3-(2H-triazol-4-yl)pyrrolidin-1-yl]methanone
[3-(4-tert-butylsulfonyl-2-chlorophenyl)azetidin-1-yl]-[(3S)-3-(2H-triazol-4-yl)pyrrolidin-1-yl]methanone (PubChem CID 175974827) has the molecular formula C20H26ClN5O3S and a molecular weight of 451.98 g/mol. Its IUPAC name is [3-(4-tert-butylsulfonyl-2-chlorophenyl)azetidin-1-yl]-[(3S)-3-(2H-triazol-4-yl)pyrrolidin-1-yl]methanone.
Molecular Properties
| Compound Name | [3-(4-tert-butylsulfonyl-2-chlorophenyl)azetidin-1-yl]-[(3S)-3-(2H-triazol-4-yl)pyrrolidin-1-yl]methanone |
|---|---|
| PubChem CID | 175974827 |
| Molecular Formula | C20H26ClN5O3S |
| Molecular Weight | 451.98 g/mol |
| Exact Mass | 451.14 |
| IUPAC Name | [3-(4-tert-butylsulfonyl-2-chlorophenyl)azetidin-1-yl]-[(3S)-3-(2H-triazol-4-yl)pyrrolidin-1-yl]methanone |
| SMILES | CC(C)(C)S(=O)(=O)c1ccc(C2CN(C(=O)N3CC[C@H](c4cn[nH]n4)C3)C2)c(Cl)c1 |
| InChI | InChI=1S/C20H26ClN5O3S/c1-20(2,3)30(28,29)15-4-5-16(17(21)8-15)14-11-26(12-14)19(27)25-7-6-13(10-25)18-9-22-24-23-18/h4-5,8-9,13-14H,6-7,10-12H2,1-3H3,(H,22,23,24)/t13-/m0/s1 |
| InChIKey | FWQPHYNISVRPQO-ZDUSSCGKSA-N |
| XLogP | 3.04 |
| TPSA | 99.26 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 451.98 |
| LogP ≤ 5 | 3.04 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 175974827 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.